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Introduction: Pelvic exenteration (PE) is the only curative treatment for certain locally advanced intra-
pelvic malignancies. PE has high morbidity, and optimal reconstruction of the pelvic floor remains
undetermined.
Materials and methods: A retrospective chart review was performed at a tertiary university center to
assess the surgical and oncological outcomes of 39 PE procedures over a 12-year period. The majority of
patients (n¼ 25) underwent transverse musculocutaneous gracilis (TMG) flap reconstruction for pelvic
floor reconstruction.
Results: The 1- and 5-year overall survival (OS) was 72% (95%CI 58%e86%) and 48% (95%CI 31%e65%),
respectively. In multivariate analysis, lymph node metastasis (HR 3.070, p¼ 0.024) and positive surgical
margins (HR 3.928, p¼ 0.009) were risk factors for OS. In this population, 71.8% of the patients had at
least one complication. The complication rate was 65.4% and 84.6% for patients with versus without flap
reconstruction, respectively (p¼ 0.191). The length of stay was longer for patients with a major
complication 16,0 ± 5,9 days vs. 29,4 ± 14,8 days, p¼ 0,001, but complications did not affect OS.
Conclusion: For selected patients, PE is a curative option for locally advanced, residual, or recurrent
intrapelvic tumors. Pelvic floor and vulvovaginal defects can reliably be reconstructed using TMG flaps.
TMG flaps are favored in our institution over abdominal-based flaps because the donor site morbidity is
reasonable and TMG does not interfere with enterostomy.
© 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical
Oncology. All rights reserved.; DFS, disease-free survival;
, overall survival; PE, pelvic
-computed tomography; PPE,
culocutaneous gracilis; TPE,
bdominis musculocutaneous;
pital, BO Box 2000, 33521,
on for Cancer Surgery, and the EurIntroduction
Complete en bloc surgical resection with clear margins is para-
mount for patient survival in advanced and recurrent pelvic ma-
lignancies [1]. Pelvic exenteration (PE) is a complex surgical
procedure involving partial or total removal of the pelvic organs.
Total pelvic exenteration (TPE) includes removal of the rectum,
genital organs, and bladder. Anterior pelvic exenteration (APE) in-
cludes partial or total removal of the vagina, removal of the uterus
and bladder. Posterior pelvic exenteration (PPE) includes partial or
total removal of the vagina, removal of the uterus and rectum.
Based on the extent of surgical resection, pelvic exenterations areopean Society of Surgical Oncology. All rights reserved.
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(infralevator with vulvectomy). PE was first described by
Brunschwig in 1948 as a palliative procedure, but PE is now per-
formed mainly in selected patients with curative intent [2,3].
PE has considerable morbidity, and the patient's quality of life is
negatively affected by one or two permanent ostomies. Further-
more, the pelvic visceral anatomy is profoundly altered, and the
integrity of the pelvic floor is weakened, creating a risk of post-
operative complications and functional problems. In contemporary
publications, the postoperative complication rates after PE range
from 56% to 94% [1,4e7], while 5-year overall survival (OS) ranges
from 22% to 62% [8e11]. The most important predictors of survival
are clear surgical margins [1,8,12] and negative lymph node status
[13].
Reconstruction after PE entails securing the pelvic floor, filling in
the dead space, and forming a neovagina in selected patients who
undergo total PE. Studies show that the results of autologous
reconstruction are superior to those of synthetic mesh- or acellular
dermal matrix-based solutions [14]. Myocutaneous flap recon-
struction has a reduced major pelvic floor wound complication rate
compared to primary closure after extensive pelvic floor resection
[15]. Flaps based on the inferior epigastric artery are most
commonly used for pelvic floor and vaginal reconstruction,
including the vertical rectus abdominis musculocutaneous (VRAM)
flap, transverse rectus abdominis musculocutaneous (TRAM) flap,
or, more recently, the deep inferior epigastric artery perforator
(DIEP) flap [15e17]. Abdominally-based flaps interfere with
abdominal wall integrity; this is noteworthy because many PE pa-
tients require urinary diversion and/or end colostomy [1,9]. Pelvic
floor reconstruction by transverse myocutaneous gracilis (TMG)
flapwas first described by Kolehmainen et al. [18]. TMG flap is often
the most feasible local option for pelvic floor and vaginal recon-
struction, and this option does not impair abdominal wall integrity
[19].
This retrospective chart review was performed to evaluate
oncological outcomes and complications related to PE and TMG flap
reconstruction in a tertiary university center over a 12-year period.
Materials and Methods
Selection criteria
This was a retrospective cohort study of all patients who un-
derwent PE surgery between January 1, 2005 and December 31,
2016 for an oncological indication at Tampere University Hospital.
The study was approved by our institutional review board (ETL
code R16582). Patients were identified from our electronic medical
records and surgical database. Preoperative evaluation included a
laboratory work-up, clinical examination of the patient, and mag-
netic resonance imaging to evaluate the size of the tumor and its
relationship with the nearby organs.Whole body positron emission
tomography-computed tomography (PET-CT) was used to exclude
distant metastasis. All patients underwent curative intent surgery.
Variables and measurements
The following data were obtained: patient demographics,
comorbidities, operative details, histopathological results, pre- and
postoperative radiotherapy, chemotherapy, and complications.
Complications were classified according to Clavien-Dindo classifi-
cation [20]. Complications classified as 3b or higher were catego-
rized as severe. All complications were collected from the date of
exenteration to the date of last contact. Disease relapse (local
relapse or metastasis) information was determined from medical
records, and deaths were identified from the national populationdatabase. Disease-free survival (DFS) was measured from the date
of exenteration to the date of recurrence, date of death or date of
last contact. OS was measured from the date of exenteration to the
date of death or date of last contact.Surgical technique
All patients are evaluated with gynecologic oncologist and
plastic surgeon prior the operation. Patients undergoing TPE
receive sexual counselling from specialized nurse and are offered
vaginal reconstruction.
The patient is placed in the dorsal lithotomy position. Colostomy
and possible uretero-ileo-cutaneostomy locations, as well as TMG
flap landmarks, are marked preoperatively. The pelvis is
approached by a midline laparotomy incision. At laparotomy, the
entire abdomen and pelvis are carefully examined for any evidence
of metastatic or intraperitoneal cancer, and the lower para-aortic
lymph nodes are sampled for frozen section analyses. If these are
negative, a bilateral pelvic lymphadenectomy is performed, and an
immediate frozen section analysis is performed to determine
whether the operation should continue. The size and location of the
tumor dictates the type (type I, II, or III) of exenteration that is
required to obtain clear surgical margins.
Once the tumor has been resected, the reconstructive team
starts the flap harvest while the oncology team performs urinary
diversion. Our TMG flap harvest technique for pelvic floor and va-
gina reconstruction has been described in detail previously [19]. For
unilateral reconstruction, a skin paddle that is approximately
8e10 cm by 20 cm is harvested with the gracilis muscle divided at
the distal part near the knee joint. A bilateral TMG flap is used for
vaginal reconstruction as well as in cases with extended perineal
skin resection. In these cases, the skin island is approximately
6e7 cm by 20 cm. Reconstruction starts with distal skin incision
and continued until muscular fascia. Fascia is opened over gracilis
muscle andmuscle is dissected all the way near knee joint. Anterior
part of the proximal skin incision is carried out to muscle fascia.
Vascular pedicle is identified under adductor muscle in it is
dissected free from surrounding tissues andmotor nerve is divided.
Rest of the skin paddle and distal muscle insertion are incised to
finalize the flap harvest. After flap harvest, a tunnel is created under
the labia, and flaps are pulled through. The posterior and anterior
parts of the skin island are de-epithelialized, and a neovagina is
formed by suturing the skin paddles together, starting from the
ventral portion of the neovagina. The posterior part of the de-
epithelialized skin is sutured to Cooper's ligaments, and the distal
portion of the muscles are sutured posteriorly to the pelvic floor
through the laparotomy wound to fill the dead space and the pelvic
floor defect and to prevent bowel herniation (Fig. 1aeh). Donor
sites are closed directly with a suction drain. Key points of the
reconstructive procedure are shown surgical video (Supplement 1).
Supplementary video related to this article can be found at
https://doi.org/10.1016/j.ejso.2019.04.021.Statistical analysis
Categorical variables were compared using a chi-square test.
Continuous variables were compared using an independent sample
t-test. DFS and OS were assessed with the Kaplan-Meier method,
and statistical significance was determined using a log-rank test.
Cox regression analysis was used to identify independent factors
affecting survival. All statistical analyses were performed using
SPSS Statistics 24.0 (IBM Armonk, NY, USA), and a p-value less than
0.05 was considered significant.
Fig. 1. PPE with most of the posterior and lateral walls resected (a) and after bilateral TMG flap reconstruction (b). Infralevator TPE (c), pelvic floor filling with de-epithelialized skin
and muscle flap viewed from abdominal cavity (d) and vaginal reconstruction (e). PPE with posterior vaginal wall resection (f) with unilateral TMG flap reconstruction (g and h).
PPE¼ posterior pelvic exenteration, TMG¼ transverse myocutaneous gracilis, TPE¼ total pelvic exenteration.
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During the 12-year study period, 38 women underwent a total
of 39 exenteration operations. One patient underwent a first APE
and then, two years later, underwent PPE after local recurrence. The
mean patient age was 59.3± 12.2 years, and the mean follow-up
was 35.1 (range 2.5e123) months. Table 1 shows the patients’ de-
mographic characteristics, comorbidities, and body mass index
(BMI) values.
Of the 39 patients, 26 (66.7%) underwent TPE, 11 (28.2%) un-
derwent PPE, and 2 (5.1%) underwent APE. The mean surgical time
was 428± 56min for TPE and 374± 49min for combined APE and
PPE (p¼ 0.032). The mean length of stay was 22.5 days for the TPE
group and 15.5 days for the combined PPE and APE groups
(p¼ 0.024). The length of stay was 16.0± 5.9) days for patients
without severe complications and 29.4± 14.8 days for patients with
severe complications (p¼ 0.001). While 15 (38.5%) patients had aTable 1
The demographic characteristics, comorbidities, body mass index values, tumor
types, and radiotherapy status of 39 patients who underwent pelvic exenteration.
Mean Range
Age 59,3 30e78
Body mass index 26,2 16,0e38,0
N %
Diabetes 4 10,3
Chronic heart disease 2 5,1
Chronic pulmonary diasease 1 2,6
Primary tumor 15 38,5
Tumor recurrence 24 61,5
Radiotherapy
Pre-operative 29 74,4
Post-operative 1 2,6
None 9 23,0primary surgical procedure, 24 (61.5%) had a secondary salvage
procedure after previously failed primary therapy. A total of 29
(74.4%) patients had pre-operative radiotherapy, and 1 (2.6%) pa-
tient had post-operative radiotherapy. Table 2 lists the primary
locations and histology of the tumors. Nine (23.1%) patients had
local lymph node metastasis.
We found that 27 (69.2%) patients underwent flap reconstruc-
tion for pelvic floor and/or vaginal reconstruction. Of these, 17
(43.6%) had bilateral TMG flap reconstruction, 9 (23.1%) had uni-
lateral TMG flap reconstruction, and 1 (2.6%) had TRAM flap
reconstruction; 12 (30.8%) patients had no flap reconstruction for
the pelvic floor defect (Fig. 2). Out of 26 patients who underwent
TPE, 12 (46,2%) had vaginal reconstruction. Bilateral TMG flap was
used for all vaginal reconstructions in the TPE group.
The 1- and 5-year DFS of all patients was 58% (95%CI 43%e74%)
and 45% (95%CI 28%e68%), respectively, and the 1- and 5-year OS of
all patients was 72% (95%CI 58%e86%) and 48% (95%CI 31%e65%),
respectively. Factors affecting OS in univariate analysis were BMI
over 30 (p¼ 0.028), lymph node metastasis (p¼ 0.048), and posi-
tive surgical margins (p¼ 0.001) (Table 4). When these were
applied to multivariate analysis, only positive surgical margins
(p¼ 0.009) and lymph node metastasis (p¼ 0.027) were significant
factors that contributed to OS (Table 4). The mean OS for patients
with negative surgical margins was 84 months (95%CI 64e105
months) versus 17months (95%CI 7.8e27months) for patients with
positive surgical margins (p< 0.001) (Fig. 3a). The 1-year OS of
patients with intralesional surgical (R2) resection (n¼ 3) was 33%
(OS range, 10e15 months). The mean OS was 20 months (95%CI
12e29 months) for patients with lymph node metastasis and 77
months (95%CI 58e97 months) for patients without lymph node
metastasis (p¼ 0,039) (Fig. 3b).
There was a total of 49 complications in 28 (71.8%) patients. The
complication rate was 65.4% and 84.6% for patients with versus
without flap reconstruction, respectively (p¼ 0.191). Prior
Table 2
Tumor histology and primary location of the tumor in 39 patients who underwent
pelvic exenteration.
Histology N %
Adenocarinoma 20 51,3
Spinocellular ca 12 30,8
Melanoma 5 12,8
Cystadenocarcinoma 2 5,1
Primary location
Cervix 12 30,8
Vagina 7 17,9
Vulva 6 15,4
Uterus 5 12,8
Rectum 5 12,8
Ovary 3 7,7
Urethra 1 2,6
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rate. A total of 12 patients (30.8%) had at least one severe compli-
cation, and the most common complications were infection (43,6%)
and local wound dehiscence (33,3%) (Table 3). There was one
complication that was directly flap-related, a minor edge necrosis
of a TMG flap that was treated with excision and direct closure. The
most severe complication of each patient according to Clavien-
Dindo classification is shown in Table 3.Discussion
PE remains the only curative alternative for certain locally
advanced, residual, or recurrent tumors of the pelvic organs,
especially those involving the female reproductive organs. Even
though a majority of the patients in this series experienced surgical
or medical complications, the 5-year OS rate approached 50% with
no perioperative mortality.
Careful patient selection, planning, and a multidisciplinary team
approach are paramount for successful PE. Patient age was notFig. 2. Exenterations and their reconstructions. TPE¼ total pelvic exenteration,
PPE¼ posterior pelvic exenteration, APE¼ anterior pelvic exenteration. TMG¼ trans-
verse myocutaneous gracilis flap, TRAM¼ transverse rectus abdominis flap.associated with an increased risk of complications or with OS,
highlighting the importance of individualized decision making for
this patient group [10,21]. Patients require close follow-up in the
post-operative period, as complications are common after PE. Pa-
tients also required interventions bymultiple specialties during the
post-operative period. The overall length of stay of 22.5 days for TPE
was similar to that in other cohorts [1,13,22].
PE can be performed for curative intent in patients who present
with advanced or recurrent pelvic malignancies. Our 5-year OS of
48% was comparable to that in larger patient cohorts [2,4]. BMI
affected OS in univariate analysis but not in multivariate analysis.
Obesity has not been shown to affect recurrence or OS in patients
who undergo PE for a gynecological indication [23]. In multivariate
analysis, only negative surgical resection margins (R0) and negative
lymph node status had a positive effect on patient survival. Both
negative surgical margins [1,9,13,24] and negative lymph node
status [13,24] have been shown to be predictive for survival.
There was a tendency toward a lower complication rate in the
flap reconstruction, cohort, although this did not reach statistical
significance. Flap closure is superior to primary closure for pelvic
floor defects following oncologic resection [15]. Reconstruction
after PE has three main goals: securing the pelvic floor in order to
prevent perineal herniation of the bowel; filling in the dead space;
and forming a vagina, either partially or entirely. A variety of
methods have been described, ranging from free skin and bowel
grafts to local flaps, muscle flaps, and myocutaneous flaps [25,26].
Of these alternatives, only vascularized fasciocutaneous or myo-
cutaneous flaps can achieve all three of these goals. Both mesh and
acellular dermal matrix have been used previously to support the
pelvic floor, but these are associated with increased infection rate
and fistulas [14]. Furthermore, autologous reconstruction is needed
for patients who want to be able to have intercourse.
The TMG flap is conveniently located in the upper thigh,
providing a pliable flap with a width of 6e10 cm and a length up to
26 cm, and, together with the gracilis muscle, has enough bulk to
fill in the pelvic floor. It can be raised as a unilateral or bilateral flap,
depending on the reconstructive requirements and the amount of
expendable tissue. We found that TMG flaps are versatile tool for
pelvic floor and vaginal reconstruction after PE. Bilateral TMG
reconstruction is indicated for TPE patients who wish to have
vaginal reconstruction and PPE patients whos vaginal resection
included, not only posterior wall of the vagina, but resection
extended to the lateral wall. Bilateral TMG flaps are also required
for some patients who undergo concomitant radical vulvectomy.
Remaining of the defects can be reliably reconstructed with uni-
lateral TMG flap. Horizontally oriented skin paddle in TMG flap was
reliable with only one minor skin edge necrosis in this series.
Reconstructing the pelvic floor and vagina with a unilateral or
bilateral TMG flap has been our preferred choice since 2011 [19].
Vaginal reconstructionwas offered to all patients with TPE and was
performed on 12 patients.
TMG flaps have two additional advantages over abdominal-
based flaps (VRAM/TRAM or DIEP flaps). First, patients undergo-
ing TPE required urinary diversion and colostomy through the
abdominal wall. Harvesting the flap from the abdomen is associ-
ated with significant donor site morbidity as it weakens the ante-
rior abdominal wall resulting abdominal wound complication rate
up to 48% [16]. Some prefer gracilis flap over abdominal flap when
bilateral ostomies are needed [27]. However, there is no clear evi-
dence that use of abdominal flap would increase abdominal her-
niation risk [15,28] Second, harvesting the TMG flaps and
reconstruction of the pelvic floor can be performed while the
urologist performs urinary diversion. Our mean surgical time of
428min was comparable to the 335e725min reported for re-
constructions with abdominal-based flaps in previously published
(B)
(A)
Fig. 3. Kaplan-Maier plots showing overall survival (OS) in patients with R0 or R1/2 resection margins (A) with or without lymph node metastasis (B).
J. Kiiski et al. / European Journal of Surgical Oncology 45 (2019) 1632e16371636series [17,29]. There are no prospective studies comparing thigh or
abdominal based flaps for pelvic floor and vaginal reconstruction.
No differences were detected on outcomes or complications when
thigh and abdominal flaps were compared in meta-analysis or
recent retrospective studies [15,27,30].
Our overall complication rate of 71.8% was similar to the rates in
previous publications [1,9,13]; notably, earlier reports did not al-
ways define complication severity. Here we stratified complication
severity using the Clavien-Dindo classification. In our cohort, the
majority of complications were minor complications, and the se-
vere complication rate was 30,8%. Severe complications prolongedthe length of stay but did not affect the DFS or OS. The most
common complications were infectious complications, and the
majority of these were managed with antimicrobial treatment.
Wound dehiscence was the most common operatively-managed
complication. There were three post-operative decubital ulcers.
We were not able to retrace the timing of these ulcers nor could we
determine whether proper preventive measures failed or whether
the decubital ulcer risk was disregarded during post-operative care.
There was only one direct flap-related complication with partial
flap loss in this cohort. Our flap-related complication rate was
lower than in series that used abdominal-based flap reconstruction
Table 3
Complications (number and percentage) and the grade of the most severe compli-
cation in 39 patients who underwent pelvic exenteration.
Complication n %
Infection 17 43,6%
Wound dehiscence 13 33,3%
Enteral fistula 3 7,7%
Postoperative decubital ulcer 3 7,7%
Acute kidney injury 2 5,1%
Pelvic evisceration 1 2,6%
Urinary fistula 1 2,6%
Urinary incontinence 1 2,6%
Cardiac insufficiency 1 2,6%
Hernia/bulging 1 2,6%
Thromboembolic complication 1 2,6%
Flap loss
Partial 1 2,6%
Total 0 0%
Clavien-Dindo grade n %
1 4 10,3%
2 8 20,5%
3a 4 10,3%
3b 10 25,6%
4a 2 5,1%
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One limitation of this study was its retrospective nature.
Although the number of patients who underwent PE during the 12-
year study period was comparable to the number in some earlier
reports [5,13], the heterogeneity of the tumor location and histol-
ogy limited its statistical power for detecting risk factors for com-
plications as well as histology-specific survival. No patient-
reported outcome measures were available for this patient cohort.
In conclusion, in carefully selected patients who are treated by
an experienced multidisciplinary team, PE is a possible curative
option for recurrent gynecological, urological, and gastrointestinal
cancers. Clear surgical margins are paramount for survival and
should be the goal in every case. Pelvic floor and vulvovaginal de-
fects can be reconstructed with TMG flaps without additional
morbidity.
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